Crown Laboratories Acquires Revance Therapeutics, Expanding Aesthetic Portfolio
The deal expands Crown’s presence in the aesthetics market, bringing Daxxify and the RHA Collection into its portfolio.
The deal expands Crown’s presence in the aesthetics market, bringing Daxxify and the RHA Collection into its portfolio.
A Stanford-trained microsurgeon will lead the division starting Sept 1, marking a leadership transition after two decades under the current chief.